Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience
Crossref DOI link: https://doi.org/10.1007/s13555-019-0310-5
Published Online: 2019-07-03
Published Print: 2019-09-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Huang, Yi-Wei
Tsai, Tsen-Fang http://orcid.org/0000-0002-1498-1474
Text and Data Mining valid from 2019-07-03
Version of Record valid from 2019-07-03
Article History
Received: 11 February 2019
First Online: 3 July 2019